Hyperthyroidism News and Research

RSS

Hyperthyroidism is a disorder that occurs when the thyroid gland makes more thyroid hormone than the body needs. It is sometimes called thyrotoxicosis, the technical term for too much thyroid hormone in the blood. About 1 percent of the U.S. population has hyperthyroidism. Women are much more likely to develop hyperthyroidism than men.

Genetics may play a role in allergic reactions to contrast media

Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast media are at risk for future reactions, according to a large study published in the journal Radiology.

4 Sep 2019

Study examines the utility of thyroid function screening in youth with mood and anxiety disorders

A new study from researchers at the University of Cincinnati and Cincinnati Children's looks at the prevalence of abnormal thyroid function in youth with severe mood and anxiety disorder.

6 Aug 2019

Study finds link between radioactive iodine doses and cancer death

Radioactive iodine has been used since the 1940s to treat hyperthyroidism, an overactive thyroid. This study is an extension of one that has followed patients in the United States and the United Kingdom treated for hyperthyroidism for nearly 70 years.

2 Jul 2019

Scientific breakthrough provides new hope for people living with multiple sclerosis

A scientific breakthrough provides new hope for millions of people living with multiple sclerosis. Researchers at Oregon Health & Science University have developed a compound that stimulates repair of the protective sheath that covers nerve cells in the brain and spinal cord.

19 Apr 2019

Pediatric patients undergoing thyroid surgery have better outcomes at high-volume centers

New research recently published in the Journal of Pediatric Surgery found that post-operative success rates of pediatric thyroid patients, particularly children who require a thyroidectomy, correlate with the institution's patient volume.

4 Apr 2019

Vanderbilt study strengthens link between thyroid function and atrial fibrillation

A study by researchers at Vanderbilt University Medical Center has strengthened the link between thyroid function and atrial fibrillation, an irregular heart rhythm that increases the risk of stroke and other heart-related complications.

24 Jan 2019

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

New research suggests link between PFAS chemicals and hyperthyroidism in pet cats

New research suggests that there may be a link between higher levels of per- and polyfluoroalkyl substances in the environment and higher levels of hyperthyroidism in pet cats as they age. The findings are published in

20 Sep 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

SNMMI recognizes contributions to nuclear medicine and molecular imaging at 2017 annual meeting

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization, recognized contributions to the field of nuclear medicine and molecular imaging during its 2017 Annual Meeting in Denver, Colorado. Several awards ceremonies were held to recognize the valuable role SNMMI members play in advancing the diagnosis and treatment of heart disease, cancer and neurological conditions.

2 Aug 2017

IBS researchers devise nanochannels for iodide transport in cell membranes

Exchange of iodide (iodine ions) between bloodstream and cells is crucial for the health of several organs and its malfunctioning is linked to goiter, hypo- and hyperthyroidism, breast cancer, and gastric cancer.

8 Jun 2017

IBS scientists uncover biological pathway that contributes to thyroid disorder

A team led by KOH Gou Young, director of the Center for Vascular Research, within the Institute for Basic Science, in collaboration with Chungnam National University, clarified the molecular mechanism to explain how the thyroid and surrounding vascular system change in the most common form of hyperthyroidism.

18 May 2017

Breakthrough therapy reduces symptoms of Graves' eye disease in clinical trials

The disease is characterized by inflammation and a buildup of tissue around the eyes that cause them to bulge painfully from their sockets.

4 May 2017

Hyperthyroidism News and Research

Further Reading

Genetics may play a role in allergic reactions to contrast media

Study examines the utility of thyroid function screening in youth with mood and anxiety disorders

Study finds link between radioactive iodine doses and cancer death

Scientific breakthrough provides new hope for people living with multiple sclerosis

Pediatric patients undergoing thyroid surgery have better outcomes at high-volume centers

Vanderbilt study strengthens link between thyroid function and atrial fibrillation

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New research suggests link between PFAS chemicals and hyperthyroidism in pet cats

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Celgene to share new and updated data around novel hematological therapies

First-ever treatment for Merkel cell carcinoma receives approval in Japan

SNMMI recognizes contributions to nuclear medicine and molecular imaging at 2017 annual meeting

IBS researchers devise nanochannels for iodide transport in cell membranes

IBS scientists uncover biological pathway that contributes to thyroid disorder

Breakthrough therapy reduces symptoms of Graves' eye disease in clinical trials

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News